Display options
Cite
O'Donnell M, Zaya R, Correia E, et al. Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study. J Am Acad Dermatol. 2021;doi: 10.1016/j.jaad.2021.07.013.
O'Donnell, M., Zaya, R., Correia, E., Krishnasamy, S., Sahu, J., Shi, W., Cha, J., Alpdogan, S. O., Porcu, P., & Nikbakht, N. (2021). Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study. Journal of the American Academy of Dermatology, . https://doi.org/10.1016/j.jaad.2021.07.013
O'Donnell, Megan, et al. "Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study." Journal of the American Academy of Dermatology vol. (2021). doi: https://doi.org/10.1016/j.jaad.2021.07.013
O'Donnell M, Zaya R, Correia E, Krishnasamy S, Sahu J, Shi W, Cha J, Alpdogan SO, Porcu P, Nikbakht N. Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study. J Am Acad Dermatol. 2021 Jul 14; doi: 10.1016/j.jaad.2021.07.013. Epub 2021 Jul 14. PMID: 34273458.
Copy Download .nbib Format: NLM
Share it on

J Am Acad Dermatol. 2021 Jul 14; doi: 10.1016/j.jaad.2021.07.013. Epub 2021 Jul 14.

Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study.

Journal of the American Academy of Dermatology

Megan O'Donnell, Romsin Zaya, Emily Correia, Shalini Krishnasamy, Joya Sahu, Wenyin Shi, Jisun Cha, Seyfettin Onder Alpdogan, Pierluigi Porcu, Neda Nikbakht

Affiliations

  1. Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennysylvania.
  2. Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennysylvania; Department of Hematology & Oncology, Thomas Jefferson University, Philadelphia, Pennysylvania.
  3. Dermatology Specialists of Alabama, Madison, Alabama.
  4. Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennysylvania.
  5. Department of Hematology & Oncology, Thomas Jefferson University, Philadelphia, Pennysylvania.
  6. Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennysylvania. Electronic address: [email protected].

PMID: 34273458 DOI: 10.1016/j.jaad.2021.07.013

Abstract

BACKGROUND: Mycosis fungoides with large-cell transformation (MF-LCT) is associated with an aggressive clinical course, yet data comparing treatment outcomes in MF-LCT are sparse.

OBJECTIVE: To compare treatment outcomes and to determine disease prevalence and characteristics associated with survival in MF-LCT.

METHODS: A retrospective review was conducted of mycosis fungoides patients from 2012 to 2020 treated at Thomas Jefferson University. Patients with histopathologic diagnosis of MF-LCT were included. Treatment outcomes were assessed by mean changes in the modified Severity Weighted Assessment Tool (mSWAT) and stage.

RESULTS: Of 171 patients with mycosis fungoides, 23 (13.4%) had histologic diagnosis of MF-LCT. The overall 5-year survival rate for MF-LCT was 74% and was not significantly associated with sex, age, or initial stage at the time of MF-LCT diagnosis. Brentuximab vedotin showed the greatest mean decrease in mSWAT (-20.53) and stage progression (change in Δ stage: -0.4) in MF-LCT compared to oral bexarotene (ΔmSWAT: +4.51; Δstage: +0.27), skin-directed therapy (ΔmSWAT: -5.93; Δstage: -0.08), and chemotherapy (ΔmSWAT: +4.97; Δstage: +0.85).

LIMITATIONS: Single-center retrospective design, and patients often on multiple treatment modalities.

CONCLUSIONS: We report superior treatment outcomes for brentuximab vedotin compared to oral bexarotene, skin-directed therapy, and chemotherapy in MF-LCT in both early and advanced disease.

Copyright © 2021. Published by Elsevier Inc.

Keywords: brentuximab vedotin; cutaneous T-cell lymphoma; large-cell transformation; mycosis fungoides

Conflict of interest statement

Conflicts of interest None disclosed.

Publication Types